The Scientific Advisory Committee (SAC) of Stand Up To Cancer has been strengthened by the addition of three new members: Drs. Armstrong, Dahlberg, and Philipson. The new experts bring critical knowledge in pediatric oncology, biostatistics, and healthcare economics to complement existing expertise.
A new research project will test a combination of two targeted therapies, teclistamab and daratumumab, to treat AL amyloidosis, a rare disease affecting approximately 4,500 people annually in the U.S. The study aims to leverage previous findings from multiple myeloma to expand understanding of this treatment option.
Researchers will collaborate on new approaches to treating head and neck cancers associated with Fanconi anemia and human papillomavirus (HPV). The funding will support research into genetic defects that cause these cancers, which have higher rates in Black people, particularly men.
The Stand Up To Cancer initiative will fund a 'Dream Team' of researchers and public awareness campaigns to increase screenings in medically underserved communities. The goal is to develop better approaches to colorectal cancer interception and make the disease preventable with simple tests, while addressing health disparities.
The FDA has approved pembrolizumab, a new immunotherapy drug, as the first-line treatment for patients with advanced colorectal cancer. This approval was made possible by early results from a phase III clinical trial funded by Stand Up To Cancer (SU2C) research.
Three new trans-Atlantic research teams will tackle neuroblastomas, Ewing sarcoma and other difficult-to-treat cancers in children. They aim to develop precision radiotherapy, re-engineer T-cells for immunotherapies and target cancer-causing gene mutations.
Catherine Marinac receives Sharp Tank Award to study health disparities in multiple myeloma and tailor interventions for diverse patient populations. The award supports research on early intervention and treatment for precursor multiple myeloma, a rare blood cancer disproportionately affecting people of color.
A new clinical trial has validated a remote genetic counseling approach, enabling women to assess their cancer risk from the comfort of their own homes. The study showed that skipping personalized counseling did not increase patients' distress and may lead to increased access for genetic testing.
Olaparib, a PARP inhibitor, targets genetic mutations in advanced prostate cancer patients with BRCA1 and BRCA2. The FDA approved the drug for homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer.
The FDA has approved encorafenib in combination with cetuximab for patients with advanced BRAF-mutated colorectal cancer. This new treatment is the result of DNA-guided personalized cancer treatment research by the SU2C-Dutch Cancer Society team.
Research highlights continued support for immunotherapy approaches to pediatric ALL and lung cancer, as well as progress in Cancer Interception. The studies aim to identify genes that may be responsible for immune suppression or activation in Bronchial premalignant lesions.
The Pancreatic Cancer Collective has awarded $16 million to four research teams pursuing preclinical work and clinical trials for new pancreatic cancer treatments. These breakthroughs aim to improve the five-year survival rate of 9%.
Researchers Dr. Leisha A. Emens and Dr. Xiang Zhang have received a Stand Up To Cancer Laura Ziskin Prize to explore the development of immune checkpoint inhibitors for breast cancer patients. Their collaboration aims to improve outcomes for breast cancer patients and reduce mortality rates.
SU2C's new health equity initiative aims to reduce racial and ethnic disparities in cancer research, addressing socio-economic, cultural, trust barriers that prevent minority participation. The organization requires grant proposals to include diverse patient recruitment and retention plans.
A new research team will focus on detecting gastric cancer at an early stage, potentially saving thousands of lives. The team will use advanced technologies to identify biomarkers in the blood that indicate the presence of gastric cancer.
SU2C Catalyst teams investigate new treatments for triple-negative breast cancer and metastatic hormone-sensitive prostate cancer, combining medicines like atezolizumab and ipatasertib with radiation and hormone therapy.
A pan-Canadian clinical trial will investigate a new way to treat metastatic breast cancer by making it impossible for breast cancer cells to manufacture proteins needed to be aggressive. The Dream Team, led by Nahum Sonenberg and Michael Pollak, aims to find ways to overcome translational dysregulation and prevent cancer spread.
Five postdoctoral scholars will collaborate with experts in physical and biomedical science to better understand the interplay between the immune system and cancers. The fellowships aim to develop new treatments using a patient's immune system to prevent, control, and treat cancer.
Researchers from Stand Up To Cancer will discuss their work on advancing immunotherapy for pediatric brain tumors, genome-wide cell-free DNA fragmentation profiling for early cancer detection, and personalized consolidation immunotherapy in localized non-small cell lung cancer. The findings highlight promising approaches to screening, ...
Stand Up To Cancer has awarded five research teams a total of $1.25 million to explore cross-cutting questions in cancer treatment through innovative collaboration. The grant program aims to bring together outstanding researchers from different teams to make use of the extraordinary talent across the SU2C community.
Researchers found that the interaction between pancreatic stellate cells and cancer cells could be exploited due to high levels of LIF, a key protein responsible for activating PSCs in cancer cells. Elevated LIF levels correlate with disease progression and chemotherapy resistance.
The Pancreatic Cancer Collective has awarded two million-dollar grants to AI teams developing tools to identify high-risk individuals with pancreatic cancer. One team will focus on rare gene variants and the other on machine learning analysis of clinical records and images.
Research highlights the development of next-generation CAR T-cells and immune profiling to overcome tumor resistance. SU2C presents work on cancer interception, convergence, and clinical trials for pancreatic, pediatric, brain, colorectal, lung, ovarian, and breast cancers.
Karin Pelka receives $50,000 fellowship for two years to study immune cell types in colorectal tumors and develop methods to enhance immunotherapy. The Peggy Prescott Early Career Scientist Award aims to accelerate research to get new therapies to patients quickly and save lives now.
Researchers have discovered a combination drug therapy that may effectively combat pancreatic cancer. The Pancreatic Cancer Collective, led by Martin McMahon and David Tuveson, has received funding to support clinical trials of the new treatment.
Drs. Silvia Formenti and Heather McArthur will collaborate on a year-long project using radiation and immunotherapy to create personalized vaccines for breast cancer patients. Their work aims to improve treatment outcomes and reduce mortality.
The SU2C Meg Vosburg T-Cell Lymphoma Dream Team is developing CAR-based immunotherapy strategies to target cancerous T cells without harming the immune system. The team aims to find a therapy that can improve outcomes in this patient population and make treatments more available.
The Pancreatic Cancer Collective has awarded $7 million in grants to seven teams of top cancer researchers. The funding will support clinical studies and accelerate the translation of research findings into treatments, with the goal of improving patient outcomes for pancreatic cancer.
Researchers from SU2C and Cancer Research Institute found that administering immunotherapy before surgery activates T-cells to hunt and destroy distant cancerous cells, preventing relapse. The approach showed encouraging outcomes in 45% of patients, with few evidence of cancer remaining upon follow-up.
The Stand Up To Cancer-St. Baldrick's Pediatric Cancer Dream Team will continue to develop new immunotherapy approaches for high-risk childhood cancers. The team has made significant contributions to the approval of CAR T-cell therapy and has identified ways to mitigate its side effects.
The Pancreatic Cancer Collective, funded by the Lustgarten Foundation and Stand Up To Cancer, will accelerate research for pancreatic cancer patients. The initiative aims to improve diagnosis and treatments, as well as support the next generation of pancreatic cancer investigators.
The SU2C Multiple Myeloma Dream Team aims to revolutionize the treatment of the incurable blood cancer by detecting precursor conditions such as MGUS or SMM. The team plans to analyze blood samples from approximately 50,000 people to identify biomarkers that can predict high-risk progression.
The SU2C Phillip A. Sharp Innovation in Collaboration Awards aim to strengthen collaboration among scientists conducting cancer research, with five teams receiving $1.25 million to work on new projects across institutional and national lines. The grants focus on synergies among researchers from different institutions and skill sets.
One hundred high school students from 28 states have been named winners in the third year of PBS' and Stand Up To Cancer's Emperor Science Award program. The recipients will work with a university scientist on a multi-week cancer research project, receive a Google Chromebook computer, and a $1,500 stipend.
Researchers Jos Jonkers and Helen Piwnica-Worms receive a grant to investigate how the immune system recognizes breast cancer. They will use imaging mass cytometry and patient-derived models to devise new treatment combinations, accelerating promising therapies to patients.
Seven multi-disciplinary teams will investigate immune system response to cancers, exploring factors such as DNA mismatch repair, tumor-specific proteins, and cytokine function. The teams will use machine learning expertise and access to terabytes of data to develop new treatments with less damage.
Researchers from four top teams receive funding to tackle cancers of the lung and pancreas using a new 'interception' approach, targeting precancerous cells before they turn into cancer cells. The initiative aims to catch cancers early, when treatment is more successful.
The inaugural SU2C Catalyst projects aim to explore new uses for powerful medicines in combination with other pharmaceutical company medicines, devices, and therapies. This program supports the selection of proposals by industry-specific sub-committees and significantly expedites the process of going from ideas to contracts to trials.
The Oncology Drugs Advisory Committee recommends approval of CAR T cell therapy for relapsed and refractory B-cell acute lymphoblastic leukemia (ALL), saving lives of children and young adults. Stand Up To Cancer and St. Baldrick's Foundation committed millions to the development of this life-saving treatment.
The Emperor Science Award program recognizes 100 high school students who will conduct research in a lab or virtually on a multi-week cancer project, receiving a computer and $1,500 stipend. The program aims to inspire students to pursue careers in cancer research.
Stand Up To Cancer has released a series of online training modules for nurses to prepare them for the unique challenges of immunotherapy. The modules, developed by Boston College William F. Connell School of Nursing, equip nurses with knowledge and skills needed to care for patients undergoing emerging cancer treatment therapies.
Four research teams will receive a grant of $250,000 over two years to support new research projects stemming from previous advances in cancer research. The award program aims to accelerate current research and development models to bring therapeutic benefits for cancer patients.
Five teams of cancer researchers received a total of $1 million to advance 'innovation in collaboration' through new research projects. The awards will support novel collaborations between senior and junior researchers, exploring questions arising from existing SU2C-supported Teams.
Ten scientists from eight institutions across the US will receive $750,000 each to support high-risk, high-reward projects in cancer research. The grants aim to accelerate innovative approaches in tumor metabolism, imaging, and mathematical models of combination drug therapy.
The SU2C Catalyst program will accelerate cancer research using funding and materials from pharmaceutical companies. Collaborative studies will investigate new compounds and approved agents for various uses, with a focus on prevention, detection and treatment.
A new ovarian cancer research team, funded by a $6 million grant, will focus on DNA repair therapies and prevention. The team aims to build on recent clinical advances with PARP inhibitors and develop a new web-based approach to genetic testing and counseling.
The $20 million SU2C-American Cancer Society Lung Cancer Dream Team will focus on targeting KRAS mutant lung cancer using a three-pronged approach. The team aims to develop novel therapies that combine targeted drug therapies with immunotherapies to improve patient outcomes.
A two-year study by the Stand Up To Cancer - Cancer Research Institute Immunology Translational Research Dream Team found that pembrolizumab removes PD-1, freeing up immune cells to kill cancer cells. The study validated a pathway to determine patient responsiveness and anticipated better drug combinations for more patients with melanoma.
A $7.6 million grant supports the validation of molecular tests for early detection of colorectal cancer, aiming to reduce mortality rates. The international Dream Team will focus on developing a blood test to identify patients who can benefit from chemotherapy after surgery.
The Van Andel Research Institute-funded epigenetics dream team will focus on epigenetic mechanisms in cells to control gene expression. The team will move forward with more extensive clinical trials in other cancer types to improve upon the progress already made.